title: [Clinical study on the early and short -- term use of antibiotics with broad spectrum in severely burned patients].
abstract: OBJECTIVE
  To investigate the prevention and treatment effects of early and short -- term use of antibiotics with broad spectrum on postburn severe infection in severely burned patients.
  
  
  METHODS
  Thirty -- five burn patients with TBSA from 50% to 95% were enrolled in the study. The patients were divided into early prevention [20 cases, antibiotics were used started from 6 postburn hours (PBH)] and delayed prevention (15 cases, antibiotics were applied after 48 PBH) groups. Plasma levels of LPS, TNFa and IL -- 8 were dynamically monitored with the concomitant observation of clinical signs of postburn sepsis.
  
  
  RESULTS
  After major burns, the plasma levels of LPS, TNFalpha and IL -- 8 increased evidently and reached the peak values on 3 similar 5 postburn days (PBD). But the levels of all above factors in the early group were obviously lower than those in the delayed group (P < 0.05 similar 0.01). The incidencies of sepsis and internal organ complications within 2 postburn weeks were much lower in the early group than those in the delayed group (P < 0.05). The subeschar bacterial quantification on 4 similar 7 PBD was evidently lower in the early group than that in the delayed group (P < 0.01).
  
  
  CONCLUSIONS
  Early and short -- term use of antibiotics with broad spectrum in severely burned patients could effectively prevent postburn severe infection and lower down the incidence of internal organ complications.
authors.affiliation: Department of Burns and Plastic Surgery, The Eighty -- First Hospital of PLA, Nan Jing, 210002, Jiang Su Provine, P.R. China.
authors.forename: G
authors.initials: G
authors.lastname: Zong
authors.forename: M
authors.initials: M
authors.lastname: Zhang
authors.forename: G
authors.initials: G
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D002056:Burns / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D016209:Interleukin-8 / Q000097:blood; D008070:Lipopolysaccharides / Q000097:blood; D008875:Middle Aged; D018805:Sepsis / Q000382:microbiology / Q000517:prevention & control*; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D016209:Interleukin-8; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha